Micro Imaging Technology is pleased to Announce the Acquisition of Cellmyx

Micro Imaging Technology, Inc. (MIT), a California-based public company, has announced its acquisition of Cellmyx, a well-regarded player in the aesthetic and regenerative medicine sector. The deal, which was disclosed on June 5, 2026, involves an undisclosed amount and is expected to enhance MIT's portfolio in the cosmetic surgical industry. Cellmyx, operating under the name Millennium Medical Technologies Inc., has built a strong reputation over its 25-year history for providing high-quality medical tools and innovative technologies.

Cellmyx specializes in autologous adipose grafting and transfer, which is a significant area of focus within regenerative medicine. The company has recently received FDA clearance for its intelliFat® BOD™ technology, which utilizes a patient's own body fat to facilitate recovery and healing in various medical procedures, including orthopedic and cosmetic surgeries. This innovative approach positions Cellmyx at the forefront of advancements in regenerative medicine, making it a strategic addition to MIT's existing offerings.

The acquisition of Cellmyx complements MIT's previous acquisition of SaltMed/SaltFacial, which was finalized in December 2025. SaltMed is known for its SaltFacial® Class II medical device that combines sea salt resurfacing, ultrasound technology, and LED phototherapy to enhance skin health without the harsh side effects associated with traditional treatments. Together, these acquisitions strengthen MIT's capabilities and market presence, allowing the company to expand its product lines both nationally and internationally.

The aesthetic and regenerative medicine sectors are experiencing significant growth, driven by increasing consumer demand for minimally invasive procedures and advancements in medical technologies. By integrating Cellmyx's innovative solutions with its existing portfolio, MIT is well-positioned to capitalize on this trend and meet the evolving needs of healthcare providers and patients alike. The combined expertise and resources of MIT and Cellmyx could lead to further innovations and improved patient outcomes in the cosmetic surgery field.

Looking ahead, this acquisition underscores MIT's commitment to expanding its footprint in the aesthetic and regenerative medicine markets. As the company continues to explore additional opportunities in these sectors, it aims to leverage its enhanced capabilities to deliver cutting-edge solutions that can significantly impact patient care and recovery. The strategic alignment of MIT and Cellmyx is likely to resonate well within the industry, potentially attracting further interest from investors and stakeholders as the market continues to evolve.